Skip to main navigation menu Skip to main content Skip to site footer
Plant Science Today (PST)

Review Articles

Vol. 13 No. 4 (2026)

Exploring Euphorbia peplus L. (Euphorbiaceae): Traditional uses, phytochemistry and therapeutic applications: A review

DOI
https://doi.org/10.14719/pst.15395
Submitted
4 May 2026
Published
29-09-2026 — Updated on 01-10-2026
Versions

Abstract

Euphorbia peplus L. (Euphorbiaceae), commonly known as petty spurge, is a cosmopolitan weed widely distributed across Iraq. Historically used in ethnomedicine, the species is recognised for the topical application of its milky latex to treat skin conditions, including warts, corns and cutaneous malignancies. Recent phytochemical profiling has identified an array of secondary metabolites, primarily complex diterpenoids, including ingenane and jatrophane esters, as well as triterpenoids, flavonoids, phenolic acids, tannins and alkaloids. Modern research has validated these traditional applications. Beyond oncology, recent preliminary studies demonstrated the probable anti-inflammatory, antimicrobial, antidiabetic and antileishmanial potential. This review systematically synthesises the ethnobotanical history, phytochemical profile and clinical milestones of E. peplus by investigating literature published from 1969 to 2026. Furthermore, it highlights recent research gaps, particularly those related to toxicological potential and non-oncological mechanisms and summarises future directions for standardised pharmaceutical formulation.

References

  1. 1. Chen YN, Lu QY, Li DM, Li YY, Pu XX, Li BT, et al. Three new diterpenoids from Euphorbia peplus. Nat. Prod. Res. 2021;35(21):3901–7. https://doi.org/10.1080/14786419.2020.1749609
  2. 2. Al-Emam A, Al-Shraim M, Eid RA, Jamil AM, Moustafa MF, Radad K. Cytotoxicity of Euphorbia peplus Extract on MCF7 Breast Cancer Cells. Folia Biol (krakow). 2019;67(3):127–39. https://doi.org/10.3409/fb_67-3.13
  3. 3. Barceloux DG. Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals. 1st ed. Wiley; 2008. p. 757.
  4. 4. Quattrocchi U. CRC World Dictionary of Medicinal and Poisonous Plants. CRC Press; 2016. P. 1690.
  5. 5. Ismaeel ZA, Aliwy SA. Study the indumentum for some species of Euphorbia L. (Euphorbiaceae) in Iraq. Iraqi J Agric Sci. 2023;54(4):906–13. https://doi.org/10.36103/ijas.v54i4.1780
  6. 6. Chen L, Liu L, Li Y, Guan S, Fan L, Qin X, et al. Macrocyclic Diterpenoids from Euphorbia peplus Possessing Activity Towards Autophagic Flux. IJMS. 2024;26(1):299. https://doi.org/10.3390/ijms26010299
  7. 7. Christenhusz MJM, Fay MF, Leitch IJ. The genome sequence of petty spurge, Euphorbia peplus L. (Euphorbiaceae). Wellcome Open Res. 2025;10:219. https://doi.org/10.12688/wellcomeopenres.24030.1
  8. 8. Schemezer GH, GUeibFakin. Plant resources of tropical Africa 11(1). Medicinal plant. Netherland; 2008.P. 279.
  9. 9. Ali A, Sayed H, Mohamed S, Zaher A. Macro- and micromorphology of the root, stem, leaf, inflorescence and fruit of Euphorbia peplus L. growing in Egypt. Bull. Pharm. Sci. Assiut. 2012;35(2):109-26. https://doi.org/10.21608/bfsa.2012.64610
  10. 10. Herrera MeV. The front yard forager: identifying, collecting, and cooking the 30 most common urban weeds. Seattle, Wash.: Skipstone; 2013.
  11. 11. Bin-Ammar A. Fatty Acid Synthase Inhibitory Activity of Euphorbia peplus and its Secondary Metabolites. Adv Pharmacol Pharm. 2024;12(4):367–79. https://doi.org/10.13189/app.2024.120409
  12. 12. Huerta A, Chiffelle Í, Arias C, Curkovic T, Araya JE. Bio efficacy of Euphorbia peplus latex as an antifeedant and insecticide against Gonipterus platensis larvae on Eucalyptus globulus. NZ J Forestry Sci. 2022;53. https://orcid.org/0000-0003-1142-4186
  13. 13. Hu D, Gao H, Yao X sheng. Biosynthesis of Triterpenoid Natural Products. In: Comprehensive Natural Products III p. 577–612. https://doi.org/10.1016/B978-0-12-409547-2.14678-5
  14. 14. Braun SA, Homey B, Gerber PA. Successful treatment of Bowen disease with ingenol mebutate. DerHautarzt. 2014;65(10):848-50. https://doi.org/10.1007/s00105-014-3509-5
  15. 15. Akhtar MS, Swamy MK. Anticancer Plants: Clinical Trials and Nanotechnolog. Singapore: Springer Singapore; 2017. p 123-125. https://doi.org/10.1007/978-981-10-8216-0
  16. 16. Khodaie L, Sharma A, Bhatia S, Al-Harrasi A. Introduction to plant‐based latex: phytochemistry, ethnopharmacology, biological, and pharmacological activities. 1st ed. New York: Jenny Stanford Publishing; 2025. https://doi.org/10.1201/9781003570714
  17. 17. Martinez JL, Maroyi A, Wagner ML. Ethnobotany: from the traditional to ethnopharmacology. 1st ed. Boca Raton: CRC Press; 2023.
  18. 18. Bussmann RW, Elachouri M, Kikvidze Z. Ethnobotany of Northern Africa and Levant Cham: Springer Nature Switzerland; 2024.
  19. 19. Bussmann RW, Paniagua-Zambrana NY, Kikvidze Z, editors. Ethnobotany of the Mountain Regions of Eastern Europe: Carpathians Cham: Springer Nature Switzerland; 2025. p. 1119.
  20. 20. Ghazanfar SA. Handbook of Arabian Medicinal Plants. 0 ed. CRC Press; 1994. p. 104.
  21. 21. Mavundza EJ, Street R, Baijnath H. A review of the ethnomedicinal, pharmacology, cytotoxicity and phytochemistry of the genus Euphorbia in southern Africa. S Afr J Bot. 2022;144:403–18. https://doi.org/10.1016/j.sajb.2021.08.029
  22. 22. Min XY, Chen YN, Li DM, Mu QY, Zhang ZT, Fang X. Chemical constituents of Euphorbia peplus. Biochem Syst Ecol.2021;98:104307. https://doi.org/10.1016/j.bse.2021.104307
  23. 23. Nagah A, Aly S. Physiological approaches to evaluate the antioxidant and antimicrobial activities of two wild Euphorbiaceous species of the Egyptian flora. Egypt. Acad. J. Biol. Sci., H. Botany. 2021;12(2):191–205. https://doi.org/10.21608/eajbsh.2021.298891
  24. 24. Parmar NS, Mossa JS, Al-Yahya MA, Al-Said MS, Tariq M, Ageel AM. Anti-inflammatory and Antipyretic Activity of Euphorbia peplus L. Int J. Crude Drug Res. 1989;27(1):9–13. https://doi.org/10.3109/13880208909053929
  25. 25. Li Y, Yu ZP, Li YP, Yu JH, Yue JM. Diterpenoids from Euphorbia peplus possessing cytotoxic and anti-inflammatory activities. Bioorg Chem.2024.;145:107194. https://doi.org/10.1016/j.bioorg.2024.107194
  26. 26. Kemboi D, Siwe-Noundou X, Krause RWM, Langat MK, Tembu VJ. Euphorbia diterpenes: An update of isolation, structure, pharmacological activities and structure–activity relationship. molecules. 2021;26(16):5055. https://doi.org/10.3390/molecules26165055
  27. 27. Hua J, Liu Y, Xiao CJ, Jing SX, Luo SH, Li SH. Chemical profile and defensive function of the latex of Euphorbia peplus. Phytochemistry.2017;136:56–64. https://doi.org/10.1016/j.phytochem.2016.12.021
  28. 28. Soni M, Singh IP, Ranjan Lal U. Naturally occurring monoterpene glycosides of plant origin. flavour & fragrance J. 2025;40(4):613–37. https://doi.org/10.1002/ffj.3862
  29. 29. Murata M, Nakai Y, Kawazu K, Ishizaka M, Kajiwara H, Abe H, et al. Loliolide, a carotenoid metabolite, Is a potential endogenous inducer of herbivore resistance. Plant Physiol. 2019;179(4):1822–33. https://doi.org/10.1104/pp.18.00837
  30. 30. Abd-Elhakim YM, Abdo Nassan M, Salem GA, Sasi A, Aldhahrani A, Ben Issa K, et al. Investigation of the in-vivo cytotoxicity and the in silico-prediction of MDM2-p53 inhibitor potential of Euphorbia peplus methanolic extract in rats. Toxins. 2019;11(11):642. https://doi.org/10.3390/toxins11110642
  31. 31. Yan Y, Peng MY, Yang Y, Zhang ZB, Zhang LL, Tang L, et al. Highly oxygenated ent-abietane diterpenoid lactones from Euphorbia peplus and their anti-inflammatory activity. Bioorg Chem. 2025;154:1079. https://doi.org/10.1016/j.bioorg.2024.107989
  32. 32. Ran X, Lu QY, Li YY, Pu XX, Guo Y, Yuan MR, et al. Euphejolkinolide A, a new ent-abietane lactone from Euphorbia peplus L. with promising biological activity in activating the autophagy-lysosomal pathway. Heliyon. 2023;9(2):e13691. https://doi.org/10.1016/j.heliyon.2023.e13691
  33. 33. Hasanuzzaman M. Climate-Resilient Agriculture, Vol 1: Crop responses and agroecological perspectives. Cham: Springer International Publishing; 2023.
  34. 34. King AJ, Brown GD, Gilday AD, Forestier E, Larson TR, Graham IA. A cytochrome P450‐mediated intramolecular carbon–carbon ring vlosure in the biosynthesis of multidrug‐resistance‐reversing lathyrane diterpenoids. ChemBioChem. 2016;17(17):1593–7. https://doi.org/10.1002/cbic.201600316
  35. 35. Fattahian M, Ghanadian M, Ali Z, Khan IA. Jatrophane and rearranged jatrophane-type diterpenes: biogenesis, structure, isolation, biological activity and SARs (1984–2019). Phytochem Rev. 2020;19(2):265–336. https://doi.org/10.1007/s11101-020-09667-8
  36. 36. Xiao Y, Zhang Y, Ji WS, Jia XN, Shan LH, Li X, et al. Discovery of myrsinane-type Euphorbia diterpene derivatives through a skeleton conversion strategy from lathyrane diterpene for the treatment of Alzheimer’s disease. Bioorg Chem. 2023;138:106595. https://doi.org/10.1016/j.bioorg.2023.106595
  37. 37. Czechowski T, Li Y, Gilday A D et al. Evolution of linear triterpenoid biosynthesis within the Euphorbia genus. Nat Commun. 2025;16:1–14. https://doi.org/10.1038/s41467-025-60708-2
  38. 38. Frezza C, Venditti A, Sciubba F, Tomai P, Antonetti M, Franceschin M, et al. Phytochemical profile of Euphorbia peplus L. collected in Central Italy and NMR semi-quantitative analysis of the diterpenoid fraction. J Pharm Biomed Anal. 2018;160:152–9. https://doi.org/10.1016/j.jpba.2018.07.059
  39. 39. Wan LS, Nian Y, Ye CJ, Shao LD, Peng XR, Geng CA, et al. Three minor diterpenoids with three carbon skeletons from Euphorbia peplus. Org Lett. 2016;18(9):2166–9. https://doi.org/10.1021/acs.orglett.6b00787
  40. 40. El-Sakhawy MA, El-Sherbiny Ateya AA, Balah MA. Implications of Euphorbia peplus and Euphorbia geniculata allelopathy on some plant species and phytopathogenic fungi. BioRes. 2025;20(3):5633–49. https://doi.org/10.15376/biores.20.3.5633-5649
  41. 41. Wan LS, Chu R, Peng XR, Zhu GL, Yu MY, Li L, et al. Pepluane and paraliane diterpenoids from Euphorbia peplus with potential anti-inflammatory activity. J Nat Prod. 2016 ;79(6):1628–34. https://doi.org/10.1021/acs.jnatprod.6b00206
  42. 42. Chen YN, Ding X, Li DM, Lu QY, Liu S, Li YY, et al. Jatrophane diterpenoids from the seeds of Euphorbia peplus with potential bioactivities in lysosomal-autophagy pathway. Nat Prod Bioprospect. 2021;11(3):357–64. https://doi.org/10.1007/s13659-021-00301-4
  43. 43. Gabr D G, AlQahtani R. A Review on: morphological, phytochemical and medical important of some wild euphorbiaceae poisonous plants. haya: Saudi J Life Sci. 2022;7(11):299–313. https://doi.org/10.36348/sjls.2022.v07i11.001
  44. 44. Baisted DJ. Sterols of Euphorbia peplus: The fate of 28-isofucosterol in phytosterol biosynthesis. Phytochemistry. 1969;8(9):1697–703. https://doi.org/10.1016/S0031-9422(00)85956-7
  45. 45. Hemmers H, Gülz PG, Marner FJ. Triterpenoids in epicuticular waxes of three European Euphorbia species. Z Naturfor C. 1988;43(11–12):799–805. https://doi.org/10.1515/znc-1988-11-1202
  46. 46. Taib T, AlSamara& R, Al-Sofi AAW. Chemical classification of some species Euphorbia in central and northern Iraq. Egypt Acad J Biol Sci H Botany. 2022;13(2):245–51. https://doi.org/10.21608/eajbsh.2022.281341
  47. 47. Kamel EM, Ahmed NA, El-Bassuony AA, Hussein OE, Alrashdi B, Ahmed SA, et al. Xanthine oxidase inhibitory activity of Euphorbia peplus L. Phenolics. CCHTS. 2022 ;25(8):1336–44. https://doi.org/10.2174/1386207324666210609104456
  48. 48. Alruhaimi RS, Mostafa-Hedeab G, Abduh MS, Bin-Ammar A, Hassanein EHM, Kamel EM, et al. A flavonoid-rich fraction of Euphorbia peplus attenuates hyperglycemia, insulin resistance, and oxidative stress in a type 2 diabetes rat model. Front Pharmacol. 2023 ;14:1204641. https://doi.org/10.3389/fphar.2023.1204641
  49. 49. Khafagy S, Gharbo S, Salam N. Phytochemical study of Euphorbia peplus. Planta Med. 1975;27(04):387–94. https://doi:10.1055/s-0028-1097820
  50. 50. Enas Rafaa Qasim, Jehan Al-Hatem, Lubna Abbas. Separation and identification of a number of alkaloids and some phenols from two species of plants of the genus Euphorbia grown in Nineveh Governorate. J Electrochem Soc. 2023;32(3):123–34. https://doi.org/10.33899/edusj.2023.140578.1367
  51. 51. Mustafa MH, Thukaa ZAJ. Phytochemical profiling and evaluation of the anticancer activity of Euphorbia peplus ethyl acetate extract against prostate cancer cells. Plant Sci Today. 2025;13(1):1-5. https://doi.org/10.14719/pst.11675
  52. 52. Han EJ, Fernando IPS, Kim HS, Lee DS, Kim A, Je JG, et al. (-)-Loliolide Isolated from Sargassum horneri Suppressed Oxidative Stress and Inflammation by Activating Nrf2/HO-1 Signaling in IFN-γ/TNF-α-Stimulated HaCaT Keratinocytes. Antioxidants. 2021;10(6):856. https://doi.org/10.3390/antiox10060856
  53. 53. Mendes De Lacerda Leite G, De Oliveira Barbosa M, Pereira Lopes MJ, De Araújo Delmondes G, et al. Pharmacological and toxicological activities of α-humulene and its isomers: A systematic review. Trends Food Sci. Technol. 2021;115:255–74. https://doi.org/10.1016/j.tifs.2021.06.049
  54. 54. Wan LS, Nian Y, Peng XR, Shao LD, Li XN, Yang J, et al. Pepluanols C–D, Two diterpenoids with two skeletons from Euphorbia peplus. Org Lett. 2018;20(10):3074–8. https://doi.org/10.1021/acs.orglett.8b01114
  55. 55. Hammadi R, Kúsz N, Dávid CZ, Behány Z, Papp L, Kemény L, et al. Ingol and Ingenol-Type Diterpenes from Euphorbia trigona Miller with Keratinocyte Inhibitory Activity. Plants. 2021;10(6):1206. https://doi.org/10.3390/plants10061206
  56. 56. Li YY, Yang Y, Sun M, Lu QY, Pu XX, Ran X, et al. Jatrophane polyesters from the leaves of Euphorbia peplus with anti-inflammatory activity. Phytochem Lett. 2022:114–9. https://doi.org/10.1016/j.phytol.2022.03.017
  57. 57. Yang Y, He S, Lin Y, Chen J, Yang R, Li X, et al. Euphorbia diterpenoids from Euphorbia peplus possessing anti-Alzheimer’s activity via targeting PPARγ and upregulating the level of ABCA1. Phytochemistry. 2026;242:114712. https://doi.org/10.1016/j.phytochem.2025.114712
  58. 58. Huang JY, Yang Y, Liang H, Pu XX, Li YY, Cai M, et al. Pepluenone, a new pepluane-type diterpenoid with inhibitory activity on the release of NO from the whole plant of Euphorbia peplus L. Tetrahedron Lett. 2023;123:154550. https://doi.org/10.1016/j.tetlet.2023.154550
  59. 59. Guan SP, Yang Y, Sun M, Cai M, Pu XX, Huang JY, et al. Euphpepluone S, a new lathyrane diterpenoid with anti-inflammatory activity from Euphorbia peplus L. Phytochem Lett. 2023:61–6. https://doi.org/10.1016/j.phytol.2023.03.011
  60. 60. Jaafar NS, Jaafar IS, Noori ZS. Cressa cretica pharmacognosy, and pharmacology (a review). Iraqi J Pharm Sci. 2021;30(2):31–40. https://doi.org/10.31351/vol30iss2pp31-40
  61. 61. Bolleddu R, Mangal AK, Abdullah S, G B, Narasimhaji ChV, Nagayya S, et al. The role of Ursolic acid, a pharmacologically active compound from Ocimum sanctum L. as a potential chemotherapeutic agent. Curr Pharm Anal. 2025;21(2):77–87. https://doi.org/10.1016/j.cpan.2025.02.001
  62. 62. Garg P, Awasthi S, Horne D, Salgia R, Singhal SS. The innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action. Biochim. Biophys. Acta - Rev. Cancer 2023;1878(4):188929. https://doi.org/10.1016/j.bbcan.2023.188929
  63. 63. Yuan Q, Liu C, Zhang Z, Chen F, Xiao Q, Zhang L, et al. Pharmacological advances of the chlorogenic acids family: current insights and future research directions. Front Pharmacol. 2025;16:1613048. https://doi.org/10.3389/fphar.2025.1613048
  64. 64. Jaafar NS, Enas J. Kadhim. A comprehensive pharmacognostic, phytochemical description, and clinical implementation of Amaranthus viridis. Iraqi J Pharm Sci. 2025;34(3):18–28. https://doi.org/10.31351/vol34iss3pp18-28
  65. 65. Cherchi M. Scopolamine. In: Otoneurology and vestibular medicine. Cham: Springer Nature Switzerland; 2025. p. 1093–93.
  66. 66. Ran X, Lu Q-Y, Li Y-Y, Pu X-X, Guo Y, Yuan M-R, et al. Euphejolkinolide A, a new ent-abietane lactone from Euphorbia peplus L. with promising biological activity in activating the autophagy-lysosomal pathway. Heliyon. 2023;9(2): e13691. https://doi.org/10.1016/j.heliyon.2023.e13691
  67. 67. Iwata M, Inoue T, Asai Y, Hori K, Fujiwara M, Matsuo S, et al. The protective role of localized nitric oxide production during inflammation may be mediated by the heme oxygenase-1 /carbon monoxide pathway. Biochem Biophys Rep. 2020;23:100790. https://doi.org/10.1016/j.bbrep.2020.100790
  68. 68. Marcinkiewicz E, Chlopicki S, Marcinkiewicz J. Nitric oxide - A pro-inflammatory and anti-inflammatory mediator. Cent EurJ Immunol. 2003;28(2):74–8.
  69. 69. Barile E, Fattorusso E, Ialenti A, Ianaro A, Lanzotti V. Paraliane and pepluane diterpenes as anti-inflammatory agents: First insights in structure–activity relationships. Bioorg Med Chem Lett. 2007;17(15):4196–200. https://doi.org/10.1016/j.bmcl.2007.05.072
  70. 70. Ali, AA, Sayed, HM, Ibrahim* SRM, Zaher AM. Chemical constituents, antimicrobial, analgesic, antipyretic, and anti-inflammatory activities of Euphorbia peplus L. Phytopharmacology 2013;4(1):69–80.
  71. 71. Aziz N, Jamil R. Biochemistry, Xanthine Oxidase. StatPearls Publishing LLC; 2023.
  72. 72. Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers: Euphorbia peplus sap is effective against skin cancers. Br J Dermatol. 2011;164(3):633–36 https://doi.org/10.1111/j.1365-2133.2010.10184.x
  73. 73. Yu JH, Wu DX, Yu ZP, Li YP, Wang YY, Yu SJ, et al. New e:b-friedo-hopane type triterpenoids from Euphorbia peplus with simiarendiol possessing significant cytostatic activity against HeLa cells by induction of apoptosis and S/G2 cell cycle arrest. Molecules. 2019;24(17):3106. https://doi.org/10.3390/molecules24173106
  74. 74. Öztürk MA, Egamberdieva D, Pesić M. Biodiversity and biomedicine: our future. San Diego: Elsevier Science & Technology; 2020. p.1.
  75. 75. Ghramh HA, Khan KA, Ibrahim EH. Biological activities of Euphorbia peplus leaves ethanolic extract and the extract fabricated gold nanoparticles (AuNPs). Molecules. 2019 Apr 11;24(7):1431. https://doi.org/10.3390/molecules24071431
  76. 76. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res. 2017;6:750. https://doi.org/10.12688/f1000research.11120.1
  77. 77. Masne T, Kumar D, Bansode D. A review of leishmaniasis: current knowledge and future directions of heterocyclic molecules. Explor Drug Sci. 2024;508–39. https://doi.org/10.37349/eds.2024.00059
  78. 78. Amin E, Moawad A, Hassan H. Biologically-guided isolation of leishmanicidal secondary metabolites from Euphorbia peplus L. Saudi Pharm J. 2017;25(2):236–40. https://doi.org/10.1016/j.jsps.2016.06.003
  79. 79. Oskay M, Oskay D, Kalyoncu F. Activity of some plant extracts against multi-drug resistant human pathogens. IJPR. 2009;8(4):293-300. https://doi.org/10.22037/ijpr.2010.825
  80. 80. Fhu CW, Ali A. fatty acid synthase: an emerging target in cancer. Molecules. 2020 Aug 28;25(17):3935. https://doi.org/10.3390/molecules25173935
  81. 81. Gouras GK, Olsson TT, Hansson O. β-amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics. 2015;12(1):3–11. https://doi.org/10.1007/s13311-014-0313-y
  82. 82. Liu M, Chen F, Yu R, Zhang W, Han M, Liu F, et al. Synthesis and cytotoxicity against K562 cells of 3-O-angeloyl-20-O-acetyl Ingenol, a derivative of ingenol mebutate. Int J Mol. Sci. 2016;19;17(8):1348. https://doi.org/10.3390/ijms17081348
  83. 83. Aditya S, Gupta S. Ingenol mebutate: A novel topical drug for actinic keratosis. Indian Dermatol Online J. 2013;4(3):246. https://doi.org/10.4103/2229-5178.115538
  84. 84. Silva VAO, Rosa MN, Martinho O, Tanuri A, Lima JP, Pianowski LF, et al. Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines. Invest New Drugs. 2019;37(5):1029–35. https://doi.org/10.1007/s10637-019-00728-0
  85. 85. Stockfleth E, Bastian M. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis. Expert Opin. Drug Metab. Toxicol.2018;14(9):911–8. https://doi.org/10.1080/17425255.2018.1508449
  86. 86. Dodds A, Chia A, Shumack S. Actinic Keratosis: Rationale and management. Dermatol Ther (Heidelb). 2014;4(1):11–31. https://doi.org/10.1007/s13555-014-0049-y
  87. 87. Figueras Nart I, Cerio R, Dirschka T, Dréno B, Lear JT, Pellacani G, et al. Defining the actinic keratosis field: a literature review and discussion. Acad Dermatol Venereol. 2018;32(4):544–63. https://doi.org/10.1111/jdv.14652
  88. 88. Skroza N, Bernardini N, Proietti I, Potenza C. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice. TCRM. 2018;14:1879–85. https://doi.org/10.2147/tcrm.s145779
  89. 89. Alves ALV, Da Silva LS, Faleiros CA, Silva VAO, Reis RM. The Role of ingenane diterpenes in cancer therapy: from bioactive secondary compounds to small molecules. Nat Prod Commun. 2022;17(7):1934578X221105691. https://doi.org/10.1177/1934578X221105691
  90. 90. Collier NJ, Ali FR, Lear JT. Ingenol mebutate: a novel treatment for actinic keratosis. Clinical Practice. 2014;11(3):295–306. https://doi.org/10.2217/cpr.14.13
  91. 91. Liang X, Grue-Sørensen G, Månsson K, Vedsø P, Soor A, Stahlhut M, et al. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer. Bioorg Med Chem Lett. 2013;23(20):5624–9. https://doi.org/10.1016/j.bmcl.2013.08.038
  92. 92. Fidler B, Golgberg T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. P & T J 2014;39(1):40–6. https://pubmed.ncbi.nlm.nih.gov/24672213/
  93. 93. Rosen R, Gupta A, Tyring S. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. J. Am. Acad. Dermatol. 2011;66:486–89. https://doi.org/10.1016/j.jaad.2010.12.038
  94. 94. Shafombabi NF, Knott M, Kapewangolo P, Sharifi-Rad J, Calina D. Ingenol mebutate in cancer therapy: mechanisms, clinical applications and future directions. Med Oncol. 2025 ;42(3):69. https://doi.org/10.1007/s12032-025-02615-6
  95. 95. Grada A, Feldman SR, Bragazzi NL, Damiani G. Patient‐reported outcomes of topical therapies in actinic keratosis: A systematic review. Dermatol Ther. 2021;34(2):e14833. https://doi.org/10.1111/dth.14833
  96. 96. Lesiak A, Maćkowska A, Bednarski I, Kolano P, Olejniczak-Staruch I, Woźniacka A, et al. Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects. Posttepy Dermatol Alergol. 2019;36(4):468–71. https://doi.org/10.5114/ada.2019.87450
  97. 97. Heron C, Feldman S. Ingenol mebutate and the treatment of actinic keratosis. J Drugs Dermatol. 2021;20(1):102–4. https://doi.org/10.36849/jdd.5328
  98. 98. Ross M. Australia’s poisonous plants, fungi and cyanobacteria: A guide to species of medical and veterinary importance CSIRO Publishing Locked Bag 10, Clayton South VIC 3169, Australia; 2020. https://doi.org/10.1071/9781486313877
  99. 99. Moustafa GG, Mohammed AT, Hadeed AHA, Kandil FH, El Kelsh EKM. Estimation of toxic hazards caused by methanolic extract of Euphorbia peplus in male albino rats. Adv Anim Vet Sci. 2015;4(1):5–11. https://doi.org/10.14737/journal.aavs/2016/4.1.5.11
  100. 100. Nawito M, Ahmed YF, Zayed SMAD, Hecker E. Dietary cancer risk from conditional cancerogens in produce of livestock fed on species of spurge (Euphorbiaceae). J Cancer Res Clin Oncol. 1998;22;124(3–4):179–85. https://doi.org/10.1007/s004320050152

Downloads

Download data is not yet available.